Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot shows promise for weight and diabetes control

NCT ID NCT06897202

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new once-weekly injection called MET097 in 133 adults with obesity or overweight and type 2 diabetes. The goal was to see if it helps with weight loss and blood sugar control compared to a placebo. Participants received either the drug or a placebo for 28 weeks, and researchers measured changes in body weight and blood sugar levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

133 people

The number who actually took part.

Started

Mar 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI ≥27.0 kg/m2 to ≤50.0 kg/m2 at screening * Type 2 diabetes mellitus (\*T2DM) for at least 3 months before screening * Glycated hemoglobin (HbA1c) value between ≥7.0% (53.0 mmol/mol) and ≤10.5% (91.3 mmol/mol) at Screening and treated with stable therapy for at least 30 days prior to Screening/Visit 1 (diet and exercise alone or in combination with metformin monotherapy and/or SGLT-2) * Stable body weight (increase or decrease ≤5 kg) within 3 months prior to screening Exclusion Criteria: * Female who is lactating or who is pregnant * Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 * Fasting triglycerides ≥ 5.6 mmol/L (≥500 mg/dL) * Poorly controlled hypertension * History of stroke * Significant cardiovascular disease including but not limited to unstable angina or valvular heart disease or has a history of myocardial infarction, coronary artery bypass graft, percutaneous coronary artery re-vascularization, or congestive heart failure * Diagnosis of Type 1 diabetes (history of ketoacidosis, hyperosmolar state/coma, or any other types of diabetes except T2DM) * History of acute or chronic pancreatitis * Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years * Relevant surgical history including all bariatric or weight loss surgeries * SGLT2 inhibitors and/or metformin * Had 1 or more episodes of hypoglycemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity in diabetes Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Advocare Berlin Medical Associates

    Berlin, New Jersey, 08009, United States

  • Bioluminux Clinical Research

    Naperville, Illinois, 60540, United States

  • CBH Health, LLC.

    Gaithersburg, Maryland, 20877, United States

  • CenExel iResearch, LLC

    Decatur, Georgia, 30030, United States

  • CenExel iResearch, LLC

    Savannah, Georgia, 31405, United States

  • Clinical Innovations, Inc dba CITrials

    Riverside, California, 92506, United States

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California, 90720, United States

  • Eagle Eye Care

    Columbia, Maryland, 21045, United States

  • EmVenio Research Centre at PRIME Healthcare

    Riverdale, Georgia, 30274, United States

  • EmVenio Research Centre at PRIME Healthcare

    Kansas City, Kansas, 66112, United States

  • EmVenio Research Centre at PRIME Healthcare

    Farmers Branch, Texas, 75234, United States

  • Emvenio Research

    Garden City, Michigan, 48135, United States

  • Eye Treatment Center

    Long Beach, California, 90807, United States

  • ForCare Clinical Research

    Tampa, Florida, 33613, United States

  • Hassman Research Institute

    Marlton, New Jersey, 08053, United States

  • KUR Research

    Bessemer, Alabama, 35022, United States

  • KUR Research, LLC

    Columbia, Maryland, 21045, United States

  • Koch Family Medicine Clinical Research

    Morton, Illinois, 61550, United States

  • Miami Eye Institute

    Hollywood, Florida, 33024, United States

  • Michael Roberts Opthamologist (Eye Exam)

    Glendale, California, 91204, United States

  • Onsite Clinical Solutions, LLC

    Charlotte, North Carolina, 28277, United States

  • Onsite Clinical Solutions, LLC (Satellite site)

    Charlotte, North Carolina, 28277, United States

  • ProSciento, Inc.

    Chula Vista, California, 91911, United States

  • Research Centers of America

    Hollywood, Florida, 33024, United States

  • Research Your Health

    Plano, Texas, 75093, United States

  • Revival Research Institute, LLC

    Sherman, Texas, 75092, United States

  • Synergy Healthcare

    Bradenton, Florida, 34209, United States

  • Velocity Clinical Research

    Omaha, Nebraska, 68134, United States

  • Velocity Clinical Research, Los Angeles

    Los Angeles, California, 90017, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.